Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AAT, AATD, absent, accuracy, admitting, Andy, antitrypsin, arch, augmentation, automating, Bellberry, Bhushan, Biden, Bilateral, BioReference, blood, bloodborne, Boston, bronchoalveolar, burdensome, buttock, callable, cheek, chosen, CI, clearance, clinial, cognate, COPD, COSO, DEBTM, Decode, degeneration, depot, Dr, dropped, ear, elastase, elastin, emphysema, equate, fibronectin, GeneDx, GmbH, Goux, house, HREC, ID, inefficient, Inflation, ITT, Japan, Jing, Justice, knee, Laurent, lavage, manifesting, manual, Marantz, MBA, MD, micro, Microsoft, mixed, moderate, NE, neck, neutrophil, obstruction, obstructive, OGTR, Ohio, OLE, OPKO, Orth, pain, pair, panacinar, peer, pertain, pharmacology, PhD, plasma, pre, prompted, propeieatry, pulmonary, Rand, ready, reclassification, ReCode, repayable, rescinding, resigned, RSA, saline, score, serum, settlement, shedding, sterile, Subtopic, Sutherland, swab, Switzerland, texture, topline, unclear, uninjected, unopposed, unprecedented, unqualified, upgrade, upheld, vacancy, vaccination, vaccine, VAS, vyjuvek, VyjuvekTM, Zealand, zygomatic
Removed:
abbreviated, argued, attestation, biosimilar, chamber, controller, corridor, creation, daily, DEB, defer, document, EBMRF, EBRP, exclusively, exempt, exemption, feature, foot, forfeiture, GMP, golden, Innovation, interchangeable, irrevocably, Jumpstart, nonbinding, package, par, parachute, Partnership, permanent, practical, predictive, promptly, prospectively, redemption, reimburse, relaxing, replicating, retrospectively, separately, St, supplement, terminating, traded, traditional, underwriter, volume, waive, York
Filing tables
Filing exhibits
KRYS similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Krystal Biotech, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: February 28, 2022 | By: | /s/ Krish S. Krishnan | ||||||
Krish S. Krishnan | ||||||||
President and Chief Executive Officer (Principal Executive Officer) |